Greater apathy, depression at diagnosis tied to cognitive decline
People with Parkinson’s disease facing anxiety, depression, apathy, and other mental health challenges when diagnosed are more likely to…
Articles by Marisa Wexler, MS
PPMI, landmark Parkinson’s study, opening to patients, adults in Canada
The Parkinson’s Progression Markers Initiative (PPMI), a landmark study from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)…
Brewery selling pilsner to support disease research, awareness month
To celebrate Parkinson’s Awareness Month, Bent Water Brewing Company is releasing a beer, called Common Hope, with the aim…
Experimental therapies bind to Parkinson’s-associated proteins
AT-04 and AT-07, experimental therapies Attralus is developing to treat Parkinson’s disease and other neurodegenerative disorders, are able…
High blood pressure, genetics are risk factors for cognitive impairment
Older age at the onset of disease, high blood pressure, poor cognitive and motor function, and mutations in the APOE…
Long-term Anavex 2-73 reduced dementia, motor symptoms
One year of treatment with Anavex 2-73 (blarcamesine) safely led to a reduction in symptom severity for 20 people…
Blocking synuclein nitrase eases paralysis in mouse study
Blocking the activity of the synuclein nitrase enzyme reduced the levels of toxic clumps of the alpha-synuclein protein and lessened…
FDA weighs in on ketamine for levodopa-induced dyskinesia
PharmaTher Holdings has received guidance from the U.S. Food and Drug Administration (FDA) on the late-stage clinical development of…
Merck team wins MJFF contest into next-level alpha-synuclein tracer
A science team at Merck (known as MSD outside North America) is the winner of an $8.5 million…
NLY01 fails to slow motor symptom progression in Phase 2 trial
A Phase 2 clinical trial of Neuraly’s NLY01 failed to show the experimental therapy was superior to a placebo…